AIM: To analyze the Hepatitis C virus (HCV) genotype distribution and transmission risk factors in a population of unselected patients in Luxembourg. METHODS: Epidemiological information (gender, age and transmission risks) were collected from 802 patients newly diagnosed for hepatitis C and living in Luxembourg, among whom 228 patients referred from prison. Genotyping using 5'noncoding (5'NC) sequencing was performed. We compared categorical data using the Fisher's exact F-test and odds ratios (OR) were calculated for evaluating association of HCV genotype and risk factors. RESULTS: The sex ratio was predominantly male (2.2) and individuals aged less than 40 years represented 49.6% of the population. Genotype 1 was predominant (53.4%) followed by genotype 3 (33%). Among risk factors, intravenous drug usage (IVDU) was the most frequently reported (71.4%) followed by medical-related transmission (17.6%) including haemophilia, transfusion recipients and other nosocomial reasons. Genotype 3 was significantly associated to IVDU (OR = 4.84, P < 0.0001) whereas genotype 1 was significantly associated with a medical procedure (OR = 2.42, P < 0.001). The HCV genotype distribution from inmate patients differed significantly from the rest of the population (Chi-square test with four degrees of freedom, P < 0.0001) with a higher frequency of genotype 3 (46.5% vs 27.5%) and a lower frequency of genotype 1 and 4 (44.7% vs 56.8% and 5.3% vs 9.6%, respectively). IVDU was nearly exclusively reported as a risk factor in prison. CONCLUSION: We report the first description of the HCV genotype distribution in Luxembourg. The repartition is similar to other European countries, with one of the highest European prevalence rates of genotype 3 (33%). Since serology screening became available in 1991, IVDU remains the most common way of HCV transmission in Luxembourg.
AIM: To analyze the Hepatitis C virus (HCV) genotype distribution and transmission risk factors in a population of unselected patients in Luxembourg. METHODS: Epidemiological information (gender, age and transmission risks) were collected from 802 patients newly diagnosed for hepatitis C and living in Luxembourg, among whom 228 patients referred from prison. Genotyping using 5'noncoding (5'NC) sequencing was performed. We compared categorical data using the Fisher's exact F-test and odds ratios (OR) were calculated for evaluating association of HCV genotype and risk factors. RESULTS: The sex ratio was predominantly male (2.2) and individuals aged less than 40 years represented 49.6% of the population. Genotype 1 was predominant (53.4%) followed by genotype 3 (33%). Among risk factors, intravenous drug usage (IVDU) was the most frequently reported (71.4%) followed by medical-related transmission (17.6%) including haemophilia, transfusion recipients and other nosocomial reasons. Genotype 3 was significantly associated to IVDU (OR = 4.84, P < 0.0001) whereas genotype 1 was significantly associated with a medical procedure (OR = 2.42, P < 0.001). The HCV genotype distribution from inmate patients differed significantly from the rest of the population (Chi-square test with four degrees of freedom, P < 0.0001) with a higher frequency of genotype 3 (46.5% vs 27.5%) and a lower frequency of genotype 1 and 4 (44.7% vs 56.8% and 5.3% vs 9.6%, respectively). IVDU was nearly exclusively reported as a risk factor in prison. CONCLUSION: We report the first description of the HCV genotype distribution in Luxembourg. The repartition is similar to other European countries, with one of the highest European prevalence rates of genotype 3 (33%). Since serology screening became available in 1991, IVDU remains the most common way of HCV transmission in Luxembourg.
Authors: Roberta Scheinmann; Holly Hagan; Corina Lelutiu-Weinberger; Rebecca Stern; Don C Des Jarlais; Peter L Flom; Shiela Strauss Journal: Drug Alcohol Depend Date: 2006-12-15 Impact factor: 4.492
Authors: M Bourlière; J M Barberin; M Rotily; V Guagliardo; I Portal; L Lecomte; S Benali; C Boustière; H Perrier; M Jullien; G Lambot; R Loyer; O LeBars; R Daniel; H Khiri; P Halfon Journal: J Viral Hepat Date: 2002-01 Impact factor: 3.728
Authors: M A Balogun; H Laurichesse; M E Ramsay; J Sellwood; D Westmoreland; W K Paver; S F Pugh; M Zuckerman; D Pillay; T Wreghitt Journal: Commun Dis Public Health Date: 2003-04
Authors: Kavita S Lole; Jyotsna A Jha; Sandhya P Shrotri; Badri N Tandon; V G Mohan Prasad; Vidya A Arankalle Journal: J Clin Microbiol Date: 2003-11 Impact factor: 5.948
Authors: Evan B Cunningham; Tanya L Applegate; Andrew R Lloyd; Gregory J Dore; Jason Grebely Journal: Nat Rev Gastroenterol Hepatol Date: 2015-03-17 Impact factor: 46.802
Authors: Van H Pham; Huyen D P Nguyen; Phat T Ho; Dien V Banh; Hoa L T Pham; Phiet H Pham; Ling Lu; Kenji Abe Journal: Jpn J Infect Dis Date: 2011 Impact factor: 1.362
Authors: J Verbeeck; L Kwanten; F D'Heygere; A Beguin; S Michiels; I Desombere; G Leroux-Roels; P Lemey; F Nevens; M Van Ranst Journal: Eur J Clin Microbiol Infect Dis Date: 2010-09-10 Impact factor: 3.267
Authors: Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott Journal: Mol Diagn Ther Date: 2009 Impact factor: 4.074
Authors: Nathalie Removille; Alain Origer; Sophie Couffignal; Michel Vaillant; Jean-Claude Schmit; Marie-Lise Lair Journal: BMC Public Health Date: 2011-05-19 Impact factor: 3.295